AI assistant
Sending…
Allogene Therapeutics, Inc. — Director's Dealing 2020
Mar 20, 2020
33378_dirs_2020-03-20_acb9c3b9-dcf6-4c26-9d2b-09d4586efb57.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2020-03-18
Reporting Person: Amado Rafael (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-18 | Common Stock | A | 30800 | $0.00 | Acquired | 135962 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-03-18 | Stock Option (Right to Buy) | $18.22 | A | 109600 | Acquired | 2030-03-17 | Common Stock (109600) | Direct |
Footnotes
F1: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.
More from Allogene Therapeutics, Inc.
Proxy Solicitation & Information Statement
2026
May 28
Board/Management Information
2026
May 28
Proxy Solicitation & Information Statement
2026
May 20
Regulatory Filings
2026
May 13
Capital/Financing Update
2026
Apr 15
Capital/Financing Update
2026
Apr 13
Capital/Financing Update
2026
Apr 13
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 4
Major Shareholding Notification
2026
Feb 17